Which immunosuppressive drug is preferred in the treatment of toxic epidermal necrolysis during COVID‐19 outbreak?

Cyclosporine is an effective and safe immunosuppressant in the management of Toxic epidermal necrolysis (TEN) during COVID‐19 outbreak for patients that intravenous immunoglobulin (IVIG) is contraindicated or is not affordable.

Detalles Bibliográficos
Autores principales: Farajzadeh, Saeedeh, Ahramiyanpour, Najmeh
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2021
Materias:
Case Reports
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8123742/
https://www.ncbi.nlm.nih.gov/pubmed/34026201
http://dx.doi.org/10.1002/ccr3.4249
_version_ 1783692993693220864
author Farajzadeh, Saeedeh
Ahramiyanpour, Najmeh
author_facet Farajzadeh, Saeedeh
Ahramiyanpour, Najmeh
author_sort Farajzadeh, Saeedeh
collection PubMed
description Cyclosporine is an effective and safe immunosuppressant in the management of Toxic epidermal necrolysis (TEN) during COVID‐19 outbreak for patients that intravenous immunoglobulin (IVIG) is contraindicated or is not affordable.
format Online
Article
Text
id pubmed-8123742
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher John Wiley and Sons Inc.
record_format MEDLINE/PubMed
spelling pubmed-81237422021-05-21 Which immunosuppressive drug is preferred in the treatment of toxic epidermal necrolysis during COVID‐19 outbreak? Farajzadeh, Saeedeh Ahramiyanpour, Najmeh Clin Case Rep Case Reports Cyclosporine is an effective and safe immunosuppressant in the management of Toxic epidermal necrolysis (TEN) during COVID‐19 outbreak for patients that intravenous immunoglobulin (IVIG) is contraindicated or is not affordable. John Wiley and Sons Inc. 2021-05-15 /pmc/articles/PMC8123742/ /pubmed/34026201 http://dx.doi.org/10.1002/ccr3.4249 Text en © 2021 The Authors. Clinical Case Reports published by John Wiley & Sons Ltd. https://creativecommons.org/licenses/by/4.0/This is an open access article under the terms of the http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited.
spellingShingle Case Reports
Farajzadeh, Saeedeh
Ahramiyanpour, Najmeh
Which immunosuppressive drug is preferred in the treatment of toxic epidermal necrolysis during COVID‐19 outbreak?
title Which immunosuppressive drug is preferred in the treatment of toxic epidermal necrolysis during COVID‐19 outbreak?
title_full Which immunosuppressive drug is preferred in the treatment of toxic epidermal necrolysis during COVID‐19 outbreak?
title_fullStr Which immunosuppressive drug is preferred in the treatment of toxic epidermal necrolysis during COVID‐19 outbreak?
title_full_unstemmed Which immunosuppressive drug is preferred in the treatment of toxic epidermal necrolysis during COVID‐19 outbreak?
title_short Which immunosuppressive drug is preferred in the treatment of toxic epidermal necrolysis during COVID‐19 outbreak?
title_sort which immunosuppressive drug is preferred in the treatment of toxic epidermal necrolysis during covid‐19 outbreak?
topic Case Reports
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8123742/
https://www.ncbi.nlm.nih.gov/pubmed/34026201
http://dx.doi.org/10.1002/ccr3.4249
work_keys_str_mv AT farajzadehsaeedeh whichimmunosuppressivedrugispreferredinthetreatmentoftoxicepidermalnecrolysisduringcovid19outbreak
AT ahramiyanpournajmeh whichimmunosuppressivedrugispreferredinthetreatmentoftoxicepidermalnecrolysisduringcovid19outbreak

Ejemplares similares